These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 34824194)

  • 1. Impact of diagnosis and treatment on response to COVID-19 vaccine in patients with BCR-ABL1-negative myeloproliferative neoplasms. A single-center experience.
    Cattaneo D; Bucelli C; Cavallaro F; Consonni D; Iurlo A
    Blood Cancer J; 2021 Nov; 11(11):185. PubMed ID: 34824194
    [No Abstract]   [Full Text] [Related]  

  • 2. Impaired response to first SARS-CoV-2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib.
    Guglielmelli P; Mazzoni A; Maggi L; Kiros ST; Zammarchi L; Pilerci S; Rocca A; Spinicci M; Borella M; Bartoloni A; Rossolini GM; Annunziato F; Vannucchi AM
    Am J Hematol; 2021 Nov; 96(11):E408-E410. PubMed ID: 34331712
    [No Abstract]   [Full Text] [Related]  

  • 3. Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution.
    Pimpinelli F; Marchesi F; Piaggio G; Giannarelli D; Papa E; Falcucci P; Pontone M; Di Martino S; Laquintana V; La Malfa A; Di Domenico EG; Di Bella O; Falzone G; Ensoli F; Vujovic B; Morrone A; Ciliberto G; Mengarelli A
    J Hematol Oncol; 2021 May; 14(1):81. PubMed ID: 34001183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccine against SARS-CoV-2 in previously infected health care workers.
    Parisi SG
    EBioMedicine; 2021 Sep; 71():103556. PubMed ID: 34454402
    [No Abstract]   [Full Text] [Related]  

  • 5. The Century of mRNA Vaccines: COVID-19 Vaccines and Allergy.
    Ortega Rodríguez NR; Audícana Berasategui MT; de la Hoz Caballer B; Valero Santiago A
    J Investig Allergol Clin Immunol; 2021 Feb; 31(1):89-91. PubMed ID: 33393485
    [No Abstract]   [Full Text] [Related]  

  • 6. Current pre-clinical and clinical advances in the BCR-ABL1-positive and -negative chronic myeloproliferative neoplasms.
    Mughal TI; Vannucchi AM; Soverini S; Bazeos A; Tibes R; Saglio G; Abdel-Wahab O; Pardanani A; Hehlmann R; Barbui T; Van Etten R; Tefferi A; Goldman JM
    Haematologica; 2014 May; 99(5):797-801. PubMed ID: 24790057
    [No Abstract]   [Full Text] [Related]  

  • 7. Measuring cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine (BNT126b2) in patients on maintenance haemodialysis.
    Martin P; Clarke C
    EBioMedicine; 2021 Sep; 71():103567. PubMed ID: 34454401
    [No Abstract]   [Full Text] [Related]  

  • 8. Concomitant BCR-ABL1 translocation and JAK2(V617F) mutation in three patients with myeloproliferative neoplasms.
    Hummel JM; Kletecka MC; Sanks JK; Chiselite MD; Roulston D; Smith LB; Czuchlewski DR; Elenitoba-Johnson KS; Lim MS
    Diagn Mol Pathol; 2012 Sep; 21(3):176-83. PubMed ID: 22847163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COVID-19 vaccines for patients with haematological conditions.
    Sun C; Pleyer C; Wiestner A
    Lancet Haematol; 2021 May; 8(5):e312-e314. PubMed ID: 33811822
    [No Abstract]   [Full Text] [Related]  

  • 10. Evidence of robust memory T-cell responses in patients with chronic myeloproliferative neoplasms following infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).
    Harrington P; Harrison CN; Dillon R; Radia DH; Rezvani K; Raj K; Woodley C; Curto-Garcia N; O'Sullivan J; Saunders J; Kordasti S; Ali S; de Lavallade H; McLornan DP
    Br J Haematol; 2021 May; 193(4):692-696. PubMed ID: 33719038
    [No Abstract]   [Full Text] [Related]  

  • 11. [Detection of BCR/ABL fusion gene by fluorescence in situ hybridization and its clinical application].
    Zhou RL; Mo YX; Lan M; Lin JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Oct; 19(5):1283-8. PubMed ID: 22040989
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Steinberg J; Thomas A; Iravani A
    Lancet; 2021 Mar; 397(10279):e9. PubMed ID: 33705696
    [No Abstract]   [Full Text] [Related]  

  • 13. Blunted humoral response after mRNA vaccine in patients with haematological malignancies.
    Kamboj M
    Lancet Haematol; 2021 Aug; 8(8):e540-e542. PubMed ID: 34224666
    [No Abstract]   [Full Text] [Related]  

  • 14. Messenger RNA vaccines against SARS-CoV-2.
    Topol EJ
    Cell; 2021 Mar; 184(6):1401. PubMed ID: 33740443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significant association of cutaneous adverse events with hydroxyurea: results from a prospective non-interventional study in BCR-ABL1-negative myeloproliferative neoplasms (MPN) - on behalf of the German Study Group-MPN.
    Stegelmann F; Wille K; Busen H; Fuchs C; Schauer S; Sadjadian P; Becker T; Kolatzki V; Döhner H; Stadler R; ; Döhner K; Griesshammer M
    Leukemia; 2021 Feb; 35(2):628-631. PubMed ID: 32616864
    [No Abstract]   [Full Text] [Related]  

  • 16. Understanding the dynamics of COVID-19; implications for therapeutic intervention, vaccine development and movement control.
    Salvamani S; Tan HZ; Thang WJ; Ter HC; Wan MS; Gunasekaran B; Rhodes A
    Br J Biomed Sci; 2020 Oct; 77(4):168-184. PubMed ID: 32942955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expansion of a BCR-ABL clone in a JAK2 V617F myeloproliferative neoplasm treated by ruxolitinib.
    Luque Paz D; Ianotto JC; Chauveau A; Guibourg B; Lecucq L; Lippert E; Ugo V
    Ann Hematol; 2016 Jan; 95(2):349-50. PubMed ID: 26459144
    [No Abstract]   [Full Text] [Related]  

  • 18. How nano can fight the virus.
    Ball P
    Nat Mater; 2021 Feb; 20(2):126. PubMed ID: 33504984
    [No Abstract]   [Full Text] [Related]  

  • 19. SARS-CoV-2-specific T cell immunity to structural proteins in inactivated COVID-19 vaccine recipients.
    Deng Y; Li Y; Yang R; Tan W
    Cell Mol Immunol; 2021 Aug; 18(8):2040-2041. PubMed ID: 34267334
    [No Abstract]   [Full Text] [Related]  

  • 20. A link between the driver mutations and dysregulated apoptosis in BCR-ABL1 negative myeloproliferative neoplasms.
    Mambet C; Matei L; Necula LG; Diaconu CC
    J Immunoassay Immunochem; 2016; 37(4):331-45. PubMed ID: 26890068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.